GVM±R in Patients With Relapsed or Refractory Aggressive NHL

Non Hodgkin Lymphoma Clinical Trial

Official title:

Liposomal Mitoxantrone Hydrochloride, Gemcitabine, Vinorelbine With or Without Rituximab (GVM±R) in Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05299164
• Other study ID #: CSPC-DED-DLBCL-K02
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: May 15, 2022
• Est. completion date: December 31, 2025

Study information

• Verified date: January 2024
• Source: Institute of Hematology & Blood Diseases Hospital, China
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, dose-escalation clinical study to evaluate the safety and efficacy of GVM±R in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL).

Description:

This is a single-arm, single-center, dose-escalation clinical study to explore the maximum tolerated dose (MTD) of liposomal mitoxantrone hydrochloride when combined with gemcitabine, vinorelbine and/or rituximab (GVM ± R) in patients with relapsed or refractory aggressive non-Hodgkin lymphoma (NHL). Liposomal mitoxantrone hydrochloride will be given on day 1 at four different doses (16 mg/m2, 18 mg/m2, 20 mg/m2,22 mg/m2) and be combined with gemcitabine, vinorelbine and/or rituximab (rituximab only in CD20+ lymphoma). The dose limited toxicity (DLT) will be evaluated after the first cycle of therapy. A maximum of 6 cycles of therapy are planned.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 18
• Est. completion date: December 31, 2025
• Est. primary completion date: December 18, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Subjects fully understand and voluntarily participate in this study and sign the informed consent

2. Age =18, =70years, no gender limitation

3. Expected survival = 3 months;

4. Histologically confirmed diagnosis of aggressive NHL.

5. Subjects with relapsed or refractory NHL. Relapsed disease is defined as the disease relapsing after CR or PR, and the duration of prior response is more than 6 months. Refractory disease can be confirmed if any of the following conditions are met: 1) no PR or CR has been obtained after previous treatment; 2) CR / PR was achieved after prior therapy, but recurred within 6 months; 3) Recurrence after hematopoietic stem cell transplantation.

6. Subjects must have at least one evaluable or measurable lesion per lugano2014 criteria: for lymph node lesions, the length and diameter should be > 1.5cm; For non-lymph node lesions, the length and diameter should be > 1.0cm;

7. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) : 0-1

8. The following baseline laboratory criteria are required: Absolute neutrophil count (ANC) =1.5×109/L, Platelet count (PLT) =75×109/ L, Hemoglobin(HB)= 80g/L, Total bilirubin (TBIL) =1.5X upper limit of normal (ULN), Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =2.5X ULN, Serum creatinine (Scr) =1.5X ULN.

Exclusion Criteria:

1. The subject had previously received any of the following anti-tumor treatments:

1. Subjects who have been treated with mitoxantrone or mitoxantrone liposomes;

2. Previously received doxorubicin or other anthracycline treatment, and the total cumulative dose of doxorubicin was more than 360 mg/m2 (1 mg doxorubicin equivalent to 2 mg epirubicin);

3. Subjects who received anti-tumor treatment (including chemotherapy, targeted therapy, glucocorticoid, traditional Chinese medicine with anti-tumor activity, etc.) or participated in other clinical trials and received trial drugs within 4 weeks before the first administration of the study drugs;

4. Subjects who received autologous hematopoietic stem cell transplantation or allogeneic hematopoietic stem cell transplantation within 100 days of the first administration of study drugs;

2. Hypersensitivity to any study drug or its components;

3. Uncontrolled systemic diseases (such as active infection, uncontrolled hypertension, diabetes, etc.)

4. Heart function and disease meet one of the following conditions:

1. Long QTc syndrome or QTc interval > 480 ms;

2. Complete left bundle branch block, grade II or III atrioventricular block;

3. Serious and uncontrolled arrhythmias requiring drug treatment;

4. New York Heart Association grade = III;

5. Cardiac ejection fraction (LVEF)# 50%;

6. A history of myocardial infarction, unstable angina pectoris, severe unstable ventricular arrhythmia or any other arrhythmia requiring treatment, a history of clinically serious pericardial disease, or ECG evidence of acute ischemia or active conduction system abnormalities within 6 months before recruitment.

9. Hepatitis B and hepatitis C active infection (defined as hepatitis B virus surface antigen positive and hepatitis B virus DNA higher than 1x103 copy/mL; hepatitis C virus RNA high than 1x103 copy/mL) 10. Human immunodeficiency virus (HIV) infection (defined as HIV antibody positive) 11. Patients with other malignant tumors, except for effectively controlled non- melanoma skin basal cell carcinoma, breast/cervical carcinoma in situ or other tumors without treatment during the past 5 years. 12. Pregnant and lactating women and patients of childbearing age who are unwilling to take contraceptive measures; 13. Unsuitable subjects for this study determined by the investigator.

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Non-Hodgkin
• Non Hodgkin Lymphoma

Intervention

Drug:
• Liposomal Mitoxantrone Hydrochloride dose level 1
Liposomal Mitoxantrone Hydrochloride 16 mg/m^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m^2) on day 1,8, every 3 weeks; Rituximab (375mg/m^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
• Liposomal Mitoxantrone Hydrochloride dose level 2
Liposomal Mitoxantrone Hydrochloride 18 mg/m^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m^2) on day 1,8, every 3 weeks; Rituximab (375mg/m^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
• Liposomal Mitoxantrone Hydrochloride dose level 3
Liposomal Mitoxantrone Hydrochloride 20 mg/m^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m^2) on day 1,8, every 3 weeks; Rituximab (375mg/m^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
• Liposomal Mitoxantrone Hydrochloride dose level 4
Liposomal Mitoxantrone Hydrochloride 22 mg/m^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m^2) on day 1,8, every 3 weeks; Rituximab (375mg/m^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;

Locations

Country	Name	City	State
China	Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC	Tianjin	Please Select

Sponsors (2)

Lead Sponsor	Collaborator
Institute of Hematology & Blood Diseases Hospital, China	CSPC Ouyi Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose (MTD)	Maximum tolerated dose (MTD) of liposomal mitoxantrone hydrochloride in GVM±R	Through the last patient complete his DLT observation, assessed up to 21 days
Secondary	Dose limited toxicities (DLTs)	adverse events (AE) defined as DLT events per protocol	Through the last patient complete his DLT observation, assessed up to 21 days
Secondary	The incidence rates of AE and SAE	AE or severe adverse events (SAE) occur since the first dose of therapy is given	up to 28 days after the last patient complete his study therapy
Secondary	Objective response rate (ORR)	Response is assessed according to the lugano criteria	up to 2 years
Secondary	Complete response rate (CRR)	Response is assessed according to the lugano criteria	: up to 2 years
Secondary	progression-free survival(PFS)	From the date of the first dose of therapy is given until disease progression, death or last follow-up	up to 2 years